IgA nephropathy judgment method using CD16b as biomarker
By detecting the free form of cell surface and peripheral blood of CD16b, blood samples combined with flow cytometry and ELISA technology are used to achieve early diagnosis of IgA kidney disease, solving the complexity and risk of renal biopsy in the prior art, and providing non-invasive , convenient testing solutions have delayed the progress of the disease.
Patent Information
- Application Number
- CN202410555840.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-07
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing diagnosis of IgA nephropathy depends on invasive renal biopsy, which is complex in operation, poor in popularity, and high detection risks, and cannot achieve early diagnosis, resulting in delayed treatment.
CD16b is used as a biomarker to obtain blood samples through blood collection, and free CD16b on the cell surface and peripheral blood is detected by flow cytometry and enzyme-linked immunosorbent assay (ELISA) to achieve the diagnosis of IgA nephropathy.
This method is convenient, non-invasive, and has a short detection cycle. It can screen IgA nephropathy in early stage, provide earlier treatment measures, reduce testing costs, and avoid the occurrence of uremia.
Smart Images

Figure CN118914556A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical testing technology, and in particular to a method for determining IgA nephropathy using CD16b as a biomarker. Background Art
[0002] IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world. Its clinical manifestations are diverse, mainly manifested as microscopic hematuria or macroscopic hematuria, which may be accompanied by varying degrees of proteinuria, hypertension and renal function damage. 20% to 40% of IgAN progress to end-stage renal disease within 20 years after diagnosis. The currently widely accepted IgAN multiple hit hypothesis is that galactose-deficient IgA1 (galactose-deficient IgA1) in the circulation of IgAN patients is the main cause of renal failure. The level of tIgA1 (Gd-IgA1) increases. Gd-IgA1, as an autoantigen, induces the production of autoantibody IgG. Gd-IgA1 combines with autoantibody IgG to form an immune complex (immune complex, Gd-IgA1-IgGIC) and deposits in the glomerular mesangial area. The deposited IC activates complement, induces the release of inflammatory factors and other pathways, ultimately leading to kidney damage. Since the adverse consequences are partly the result of delayed diagnosis, early diagnostic strategies are urgently needed to lead to timely medical intervention.
[0003] At present, the diagnosis of IgAN mainly relies on invasive renal biopsy, that is, direct renal biopsy. However, renal puncture is a relatively complex and technically demanding examination method, which generally needs to be carried out in cooperation with hospitals at or above the third level and their related testing institutions, and is not widely used. In addition, renal puncture is an invasive detection method, which involves risks. The subjects may suffer physical pain and may also cause internal bleeding. Therefore, the existing invasive renal biopsy is complicated to operate, has poor practicality, and has high detection risks. At the same time, since some of the adverse results are the result of delayed diagnosis, the existing diagnostic methods cannot diagnose IgAN early and cannot provide patients with active treatment measures.
[0004] In summary, developing a method for determining IgA nephropathy using CD16b as a biomarker is still a key issue that needs to be urgently addressed in the field of medical testing technology. Summary of the invention
[0005] In view of the problems existing in the prior art, the object of the present invention is to provide a method for determining IgA nephropathy using CD16b as a biomarker.
[0006] To achieve the above object, the present invention provides the following technical solutions:
[0007] A method for determining IgA nephropathy using CD16b as a biomarker comprises the following steps:
[0008] S1. Reagent preparation: Select an appropriate biomarker kit;
[0009] S2. Collect part of the subject's blood as a biological sample by blood sampling;
[0010] S3, detecting cell surface CD16b by flow cytometry;
[0011] S4, detection of peripheral blood free CD16b, i.e. peripheral blood sCD16b, by enzyme-linked immunosorbent assay (ELISA);
[0012] S5. Based on the expression of cell surface CD16b and peripheral blood free CD16b, the two are combined to achieve the diagnosis of IgAN.
[0013] The present invention is further configured as follows: in step S1, the biomarker kit includes: a flow cytometry separation reagent for neutrophil CD16b, an antibody for identifying free CD16b in peripheral blood, a washing solution, a diluent, a blocking solution, a stopping solution and a developing solution, and before performing biological sample testing, it is necessary to ensure the reagent quality and the reagent validity period in the biomarker kit, and the biological sample needs to be properly pretreated to extract the target analyte.
[0014] The present invention is further configured as follows: in step S3, the following steps are included:
[0015] S30, primary cell resuspension: After the cells of the sample to be tested are processed and counted, the cells are resuspended in cell washing solution to a cell concentration of 1×10 7 / mL;
[0016] S31. Control setting: Take 100 μL of the above resuspended cells from each of the blank control tube, isotype control tube, and sample tube to be tested, so that the number of cells in each tube reaches 1×10 6 / Tube;
[0017] S32. Primary antibody incubation: No antibody was added to the blank control tube. 5 μL of isotype antibody and CD16b antibody were added to the isotype control tube and the sample tube to be tested, respectively, and mixed thoroughly. Incubate at room temperature for 30 minutes. During the incubation period, shake the reaction tube every 10 minutes to allow the cells and antibodies to react fully.
[0018] S33, one cell washing: add appropriate amount of cell washing solution, centrifuge at 1000 rpm for 5 min, discard the supernatant, and repeat washing twice;
[0019] S34, secondary cell resuspension: resuspend the cells in 100 μL cell washing buffer;
[0020] S35, secondary antibody incubation: add appropriate amount of fluorescent labeled secondary antibody to three reaction tubes respectively, mix well, incubate at room temperature in the dark for 30 min, and shake the reaction tube every 10 min during the incubation period;
[0021] S36, secondary cell washing: add appropriate amount of cell washing solution, centrifuge at 1000 rpm for 5 min, discard the supernatant, and repeat washing twice;
[0022] S37, on-machine testing: After resuspending the cells with 100μL cell washing solution, test on the machine, first test the blank control tube and the isotype control tube, and then test the sample tube to be tested.
[0023] The present invention is further configured as follows: in step S30, the cell washing solution is a phosphate buffered saline solution (PBS) containing 2% bovine serum albumin (BSA).
[0024] The present invention is further configured as follows: in step S4, the following steps are included:
[0025] S40, sample addition: add 50 μL of standard / sample diluent to the blank well of the ELISA plate, add 50 μL of standard / sample to be tested to the remaining wells of the ELISA plate, apply sealing glue, and place at 37°C for 60 min;
[0026] S41, one-time plate washing: add 300 μL of washing solution to each well of the ELISA plate and shake and soak for 2 min, then print dry on filter paper;
[0027] S42, primary antibody addition: add 100 μL of mouse anti-human CD16b antibody dilution to each well of the ELISA plate and place at 37°C for 60 min;
[0028] S43, secondary plate washing: add 300 μL of washing solution to each well of the ELISA plate and shake and soak for 2 min, then print dry on filter paper;
[0029] S44, secondary antibody addition: add 100 μL of goat anti-mouse IgG diluent to each well of the ELISA plate and place at 37°C for 60 min;
[0030] S45, add horseradish peroxidase HRP: add 100 μL 1x biotinylated antibody working solution to each well and apply sealing glue;
[0031] S46, three washes: add 300 μL of washing solution to each well of the ELISA plate and shake and soak for 2 min, then print dry on filter paper;
[0032] S47, color development: add 100 μL of the pre-prepared specific substrate to each well, affix the sealing tape, mix well and place in the dark at 37°C for 10-20 minutes. The enzyme catalyzes a color reaction, and the specific color development time depends on the color development result;
[0033] S48, stop reaction: add 100 μL stop solution to each well and mix well to stop the reaction, block the oxidation reaction of the substrate, and maintain stable color production;
[0034] S49. Within 30 minutes of the above-mentioned termination reaction, measure the absorbance value of the generated pigment, i.e., OD value, at 450 nm using an enzyme reader.
[0035] The present invention is further configured as follows: in step S47, the specific substrate is a TMB mixture or an ABTS mixture, the TMB mixture is 3,3',5,5'-tetramethylbenzenediamine, and the ABTS mixture is 2,2'-hydrazinobis(2-methylpropionyloxy)ethane ammonium sulfonate.
[0036] The present invention is further configured as follows: in step S48, when performing result judgment and calculation, a standard curve is drawn with the standard concentration as the horizontal axis and the OD value as the vertical axis, and the corresponding content is calculated according to the sample OD value and then multiplied by the dilution multiple.
[0037] Beneficial Effects
[0038] Compared with the known public technology, the technical solution provided by the present invention has the following beneficial effects:
[0039] In the present invention, a portion of the subject's blood is collected as a biological sample for determination by blood sampling. As an important body fluid, blood is not only easy to sample and has high patient acceptance, but also can be collected at any time to detect changes in the condition. The detection of serum markers has great value in the diagnosis and disease assessment of IgAN. After obtaining the serum markers, a biomarker kit is used to detect cell surface CD16b by flow cytometry, and peripheral blood sCD16b is detected by enzyme-linked immunosorbent assay ELISA. According to the expression of cell surface CD16b and peripheral blood free CD16b, the two are combined to achieve the diagnosis of IgAN. The present invention By detecting the expression levels of the biomarkers cell surface CD16b and peripheral blood free CD16b, the combination of cell surface CD16b and peripheral blood sCD16b can provide a more efficient prediction for the diagnosis of IgAN, and can determine whether the subjects of the biological sample have IgAN, which is helpful for early screening of the disease and helps clinicians to quickly understand the patient's condition. At the same time, the detection and judgment method is convenient, the detection cycle is short, and the detection cost is reduced. Compared with traditional methods such as renal biopsy, this method is simple to operate, non-invasive, highly practical, and can repeatedly detect changes in the disease. At the same time, it can predict the occurrence and development of IgAN earlier, provide active treatment measures earlier, delay disease progression, and the occurrence of uremia. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 A flow chart of a method for determining IgA nephropathy using CD16b as a biomarker;
[0041] Figure 2 A schematic diagram of a method for determining IgA nephropathy using CD16b as a biomarker showing that CD16b is highly expressed in IgAN patients;
[0042] Figure 3 A schematic diagram of a method for determining IgA nephropathy using CD16b as a biomarker showing that blood CD16b is highly expressed in IgAN patients;
[0043] Figure 4 The figure is a ROC curve diagram of a method for determining IgA nephropathy using CD16b as a biomarker;
[0044] Figure 5 This is the area under the ROC curve of a method for determining IgA nephropathy using CD16b as a biomarker. DETAILED DESCRIPTION
[0045] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0046] The present invention will be further described below in conjunction with the embodiments.
[0047] Example
[0048] Please refer to Figure 1 As shown, a method for determining IgA nephropathy using CD16b as a biomarker comprises the following steps:
[0049] Step 1: Reagent preparation: Select an appropriate biomarker kit, which includes: flow cytometry separation of neutrophil CD16b reagent, antibody for identifying free CD16b in peripheral blood, washing solution, diluent, blocking solution, stop solution and color development solution;
[0050] Among them, before conducting biological sample testing, it is necessary to ensure the reagent quality and reagent validity period in the biomarker kit, and the biological sample needs to be properly pretreated to extract the target analyte.
[0051] Step 2: Take part of the subject's blood as a biological sample by blood sampling.
[0052] Step 3: Detecting cell surface CD16b by flow cytometry, including the following steps:
[0053] S30, primary cell resuspension: After the cells of the sample to be tested are processed and counted, the cells are resuspended in cell washing solution to a cell concentration of 1×10 7 / mL;
[0054] The cell washing solution is phosphate buffered saline (PBS) containing 2% bovine serum albumin (BSA);
[0055] S31. Control setting: Take 100 μL of the above resuspended cells from each of the blank control tube, isotype control tube, and sample tube to be tested, so that the number of cells in each tube reaches 1×10 6 / Tube;
[0056] S32. Primary antibody incubation: No antibody was added to the blank control tube. 5 μL of isotype antibody and CD16b antibody were added to the isotype control tube and the sample tube to be tested, respectively, and mixed thoroughly. Incubate at room temperature for 30 minutes. During the incubation period, shake the reaction tube every 10 minutes to allow the cells and antibodies to react fully.
[0057] S33, one cell washing: add appropriate amount of cell washing solution, centrifuge at 1000 rpm for 5 min, discard the supernatant, and repeat washing twice;
[0058] S34, secondary cell resuspension: resuspend the cells in 100 μL cell washing buffer;
[0059] S35, secondary antibody incubation: add appropriate amount of fluorescent labeled secondary antibody to three reaction tubes respectively, mix well, incubate at room temperature in the dark for 30 min, and shake the reaction tube every 10 min during the incubation period;
[0060] S36, secondary cell washing: add appropriate amount of cell washing solution, centrifuge at 1000 rpm for 5 min, discard the supernatant, and repeat washing twice;
[0061] S37, on-machine testing: After resuspending the cells with 100μL cell washing solution, test on the machine, first test the blank control tube and the isotype control tube, and then test the sample tube to be tested.
[0062] Step 4: Detecting peripheral blood free CD16b, i.e. peripheral blood sCD16b, by enzyme-linked immunosorbent assay (ELISA), comprising the following steps:
[0063] S40, sample addition: add 50 μL of standard / sample diluent to the blank well of the ELISA plate, add 50 μL of standard / sample to be tested to the remaining wells of the ELISA plate, apply sealing glue, and place at 37°C for 60 min;
[0064] S41, one-time plate washing: add 300 μL of washing solution to each well of the ELISA plate and shake and soak for 2 min, then print dry on filter paper;
[0065] S42, primary antibody addition: add 100 μL of mouse anti-human CD16b antibody dilution to each well of the ELISA plate and place at 37°C for 60 min;
[0066] S43, secondary plate washing: add 300 μL of washing solution to each well of the ELISA plate and shake and soak for 2 min, then print dry on filter paper;
[0067] S44, secondary antibody addition: add 100 μL of goat anti-mouse IgG diluent to each well of the ELISA plate and place at 37°C for 60 min;
[0068] S45, add horseradish peroxidase HRP: add 100 μL 1x biotinylated antibody working solution to each well and apply sealing glue;
[0069] S46, three washes: add 300 μL of washing solution to each well of the ELISA plate and shake and soak for 2 min, then print dry on filter paper;
[0070] S47, color development: add 100 μL of the pre-prepared specific substrate to each well, affix the sealing tape, mix well and place in the dark at 37°C for 10-20 minutes. The enzyme catalyzes a color reaction, and the specific color development time depends on the color development result;
[0071] The specific substrate is a TMB mixture or an ABTS mixture, the TMB mixture is 3,3',5,5'-tetramethylbenzidine, and the ABTS mixture is 2,2'-hydrazinobis(2-methylpropionyloxy)ethane sulfonate ammonium;
[0072] S48, stop reaction: add 100 μL stop solution to each well and mix well to stop the reaction, block the oxidation reaction of the substrate, and maintain stable color production;
[0073] S49, within 30 minutes of the termination reaction, measuring the absorbance value of the generated pigment at 450 nm using an ELISA reader, i.e., the OD value;
[0074] When judging and calculating the results, a standard curve is drawn with the concentration of the standard as the horizontal axis and the OD value as the vertical axis. The corresponding content is calculated according to the OD value of the sample and then multiplied by the dilution factor.
[0075] Step 5: Based on the expression of cell surface CD16b and peripheral blood free CD16b, the two are combined to achieve the diagnosis of IgAN.
[0076] IgG receptor expression test in IgAN
[0077] Please refer to Figure 2 - Figure 5 , related work was carried out on the expression of IgG receptors in IgAN, RNA sequencing and PCR verification were performed respectively, and the relevant data were recorded in Table 1;
[0078] Table 1 RNA sequencing data record table
[0079]
[0080] From the RNA sequencing results and PCR validation results in Table 1 , it can be seen that the Fc receptor with the greatest expression difference in IgAN patients is FcγRIIIb (FCGR3B), that is, FCGR3B has the greatest expression difference in IgA nephropathy.
[0081] In the present invention, a method for determining IgA nephropathy using CD16b as a biomarker, CD16b, also known as FcγRIIIb, is expressed in neutrophils and is the main receptor for autoantibody IgG on neutrophils. When neutrophils are stimulated, they are rapidly shed to form circulating soluble CD16b (sCD16b), which is a classic indicator of neutrophil activation and an ideal marker for measuring extracellular domain shedding; Figure 2 This is a schematic diagram showing the high expression of CD16b in IgAN patients. Figure 2 The left side in the middle indicates high CD16b+ expression in healthy controls, and the right side indicates high CD16b+ expression in IgA patients; Figure 3 This is a schematic diagram showing the high expression of blood CD16b in IgAN patients. Figure 3 The left side in the middle shows the plasma log FcgRIIIb content in IgA patients, and the right side shows the plasma log FcgRIIIb content in healthy controls; Figure 4 is the ROC curve diagram, Figure 4 The sources of the curves from top to bottom in the middle are peripheral blood sCD16b, CD16b, Upro and CD16 respectively; Figure 5 is the area under the ROC curve; Figure 2 It can be seen that the high expression of CD16b+ in IgA patients is higher than that in healthy controls. Figure 3 It can be seen that the plasma logarithmic FcgRIIIb content in IgA patients is higher than that in healthy controls. Figure 4 It can be seen that under the same specificity, peripheral blood sCD16b
[0082] and CD16b are more sensitive, Figure 5 It can be seen that the areas of peripheral blood sCD16b and CD16b are the largest in the test results;
[0083] Therefore, in the present invention, the Fc receptor with the largest expression difference of FcγRIIIb in IgAN patients was found by using RNA sequencing results and PCR verification results. At the same time, the cell surface CD16b was detected by flow cytometry detection method, and it was found that CD16b was highly expressed on the surface of neutrophils in IgA nephropathy patients. The peripheral blood free CD16b, i.e. peripheral blood sCD16b, was detected by enzyme-linked immunosorbent assay ELISA. The results showed that sCD16b (FcγRIIIb) was expressed more in IgAN. Therefore, when predicting the disease of IgAN patients with sCD16b by the judgment method of the present invention, the combined area under the ROC curve of cell surface CD16b and peripheral blood sCD16b was the largest, and the prediction value was the best;
[0084] At the same time, the present invention uses blood sampling to take part of the subject's blood as a biological sample for judgment. As an important body fluid, blood is not only easy to sample and has high patient acceptance, but also can be collected at any time to detect changes in the condition. The detection of serum markers has great value in the diagnosis and disease assessment of IgAN. After obtaining the serum markers, a biomarker kit (the kit includes: a flow cytometry separation neutrophil CD16b reagent, an antibody for identifying free CD16b in peripheral blood, a washing solution, a diluent, a blocking solution, a stopping solution and a color developing solution) is used to detect cell surface CD16b by a flow cytometric detection method, and peripheral blood free CD16b, i.e., peripheral blood sCD16b, is detected by an enzyme-linked immunosorbent assay ELISA. According to the detection of cell surface CD16b The present invention combines the expression of free CD16b on the cell surface and the expression of free CD16b in peripheral blood to realize the diagnosis of IgAN. The present invention detects the expression level of biomarkers (cell surface CD16b and free CD16b in peripheral blood), combines cell surface CD16b and peripheral blood sCD16b to provide a more efficient prediction for the diagnosis of IgAN, and can judge whether the subject of the biological sample suffers from IgAN, which is helpful for the early screening of the disease and helps clinicians to quickly grasp the patient's condition. At the same time, the detection and judgment method is convenient, the detection cycle is short, and the detection cost is reduced. Compared with traditional methods such as renal biopsy, the operation is simple, non-invasive, and practical. It can repeatedly detect changes in the condition. At the same time, it can predict the occurrence and development of IgAN in advance, provide active treatment measures earlier, delay the progression of the disease, and the occurrence of uremia.
[0085] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some of the technical features may be replaced by equivalents. Such modifications or replacements will not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for determining IgA nephropathy using CD16b as a biomarker, characterized in that: The following steps are involved: S1. Reagent preparation: Select an appropriate biomarker kit; S2. Collect part of the subject's blood as a biological sample by blood sampling; S3, detecting cell surface CD16b by flow cytometry; S4, detection of peripheral blood free CD16b, i.e. peripheral blood sCD16b, by enzyme-linked immunosorbent assay (ELISA); S5. Based on the expression of cell surface CD16b and peripheral blood free CD16b, the two are combined to achieve the diagnosis of IgAN.
2. The method for determining IgA nephropathy using CD16b as a biomarker according to claim 1, characterized in that: In step S1, the biomarker kit includes: a flow cytometry separation reagent for neutrophil CD16b, an antibody for identifying free CD16b in peripheral blood, a washing solution, a diluent, a blocking solution, a stopping solution and a color developing solution. Before performing biological sample testing, the quality and validity period of the reagents in the biomarker kit need to be ensured, and the biological sample needs to be properly pretreated to extract the target analyte.
3. The method for determining IgA nephropathy using CD16b as a biomarker according to claim 1, characterized in that: In step S3, the following steps are included: S30, primary cell resuspension: After the cells of the sample to be tested are processed and counted, the cells are resuspended in cell washing solution to a cell concentration of 1×10 7 / mL; S31. Control setting: Take 100 μL of the above resuspended cells from each of the blank control tube, isotype control tube, and sample tube to be tested, so that the number of cells in each tube reaches 1×10 6 / Tube; S32. Primary antibody incubation: No antibody was added to the blank control tube. 5 μL of isotype antibody and CD16b antibody were added to the isotype control tube and the sample tube to be tested, respectively, and mixed thoroughly. Incubate at room temperature for 30 minutes. During the incubation period, shake the reaction tube every 10 minutes to allow the cells and antibodies to react fully. S33, one cell washing: add appropriate amount of cell washing solution, centrifuge at 1000 rpm for 5 min, discard the supernatant, and repeat washing twice; S34, secondary cell resuspension: resuspend the cells in 100 μL cell washing buffer; S35, secondary antibody incubation: add appropriate amount of fluorescent labeled secondary antibody to three reaction tubes respectively, mix well, incubate at room temperature in the dark for 30 min, and shake the reaction tube every 10 min during the incubation period; S36, secondary cell washing: add appropriate amount of cell washing solution, centrifuge at 1000 rpm for 5 min, discard the supernatant, and repeat washing twice; S37, on-machine testing: After resuspending the cells with 100μL cell washing solution, test on the machine, first test the blank control tube and the isotype control tube, and then test the sample tube to be tested.
4. The method for determining IgA nephropathy using CD16b as a biomarker according to claim 3, characterized in that: In step S30, the cell washing solution is a phosphate buffered saline solution (PBS) containing 2% bovine serum albumin (BSA).
5. The method for determining IgA nephropathy using CD16b as a biomarker according to claim 1, characterized in that: In step S4, the following steps are included: S40, sample addition: add 50 μL of standard / sample diluent to the blank well of the ELISA plate, add 50 μL of standard / sample to be tested to the remaining wells of the ELISA plate, apply sealing glue, and place at 37°C for 60 min; S41, one-time plate washing: add 300 μL of washing solution to each well of the ELISA plate and shake and soak for 2 min, then print dry on filter paper; S42, primary antibody addition: add 100 μL of mouse anti-human CD16b antibody dilution to each well of the ELISA plate and place at 37°C for 60 min; S43, secondary plate washing: add 300 μL of washing solution to each well of the ELISA plate and shake and soak for 2 min, then print dry on filter paper; S44, secondary antibody addition: add 100 μL of goat anti-mouse IgG diluent to each well of the ELISA plate and place at 37°C for 60 min; S45, add horseradish peroxidase HRP: add 100 μL 1x biotinylated antibody working solution to each well and apply sealing glue; S46, three washes: add 300 μL of washing solution to each well of the ELISA plate and shake and soak for 2 min, then print dry on filter paper; S47, color development: add 100 μL of the pre-prepared specific substrate to each well, affix the sealing tape, mix well and place in the dark at 37°C for 10-20 minutes. The enzyme catalyzes a color reaction, and the specific color development time depends on the color development result; S48, stop reaction: add 100 μL stop solution to each well and mix well to stop the reaction, block the oxidation reaction of the substrate, and maintain stable color production; S49. Within 30 minutes of the above-mentioned termination reaction, measure the absorbance value of the generated pigment, i.e., OD value, at 450 nm using an enzyme reader.
6. The method for determining IgA nephropathy using CD16b as a biomarker according to claim 5, characterized in that: In step S47, the specific substrate is a TMB mixed solution or an ABTS mixed solution, the TMB mixed solution is 3,3',5,5'-tetramethylbenzidine, and the ABTS mixed solution is 2,2'-hydrazinobis(2-methylpropionyloxy)ethane ammonium sulfonate.
7. The method for determining IgA nephropathy using CD16b as a biomarker according to claim 5, characterized in that: In step S48, when judging and calculating the results, a standard curve is drawn with the concentration of the standard as the horizontal axis and the OD value as the vertical axis, and the corresponding content is calculated according to the OD value of the sample and then multiplied by the dilution factor.
